News Coverage from ACC 2024 - Alberto Foà, MD, PhD: Understanding Hypotension, Benefit, and LVEF in PARAGON-HF
Results from PARAGON-HF suggest a higher left ventricular ejection fraction (LVEF) was associated with an increased risk of hypotension and attenuated clinical benefit among patients with heart failure treated with sacubitril/valsartan (Entresto).
The data were presented by Alberto Foà, MD, PhD, a research fellow Brigham and Women’s Hospital, Harvard Medical School, at the American College of Cardiology’s (ACC) 2024 Annual Scientific Session in Atlanta, Georgia.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
